Pd72-09 early outcomes of focal brachytherapy for localized prostate cancer: comparison with whole gland brachytherapy.

You have accessJournal of UrologyProstate Cancer: Localized: Radiation Therapy II1 Apr 2017PD72-09 EARLY OUTCOMES OF FOCAL BRACHYTHERAPY FOR LOCALIZED PROSTATE CANCER: COMPARISON WITH WHOLE GLAND BRACHYTHERAPY. Victor Srougi, Eric Barret, Mohammed Baghdadi, Igor Nunes-Silva, Silvia Garcia-Barreras, Gregory Rembeyo, François Rozet, Marc Galiano, Rafael Sanchez-Salas, Jean Cosset, and Xavier Cathelineau Victor SrougiVictor Srougi More articles by this author , Eric BarretEric Barret More articles by this author , Mohammed BaghdadiMohammed Baghdadi More articles by this author , Igor Nunes-SilvaIgor Nunes-Silva More articles by this author , Silvia Garcia-BarrerasSilvia Garcia-Barreras More articles by this author , Gregory RembeyoGregory Rembeyo More articles by this author , François RozetFrançois Rozet More articles by this author , Marc GalianoMarc Galiano More articles by this author , Rafael Sanchez-SalasRafael Sanchez-Salas More articles by this author , Jean CossetJean Cosset More articles by this author , and Xavier CathelineauXavier Cathelineau More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2017.02.3189AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Focal brachytherapy (FBT) emerged as a reasonable option to treat patients with favorable prostate cancer (PCa). The aim of this study is to evaluate the early functional and oncological outcomes of FBT in the treatment of localized PCa. METHODS A retrospective review was performed at our prospective collected PCa database, searching for patients treated with FBT between 2010 and 2015. A cohort of 100 individuals treated with whole gland brachytherapy (WBT) in the same period was assessed in order to perform a comparison. IPSS, ICS and IIEF5 questionnaires were used to evaluate urinary symptoms, continence and sexual function, respectively, at 6, 12 and 24 months. All patients in the FBT group had a control prostate biopsy; PCa recurrence was defined as positive biopsy at the same treatment site. In the WBT group, PCa recurrence was defined by PSA increase > nadir + 2. RESULTS Forty patients were included in the FBT group with complete oncological follow-up. Twenty-seven patients had completed questionnaires with 24 months of follow-up (included in the functional assessment). Initial presentation and treatment characteristics are exhibited on table 1. Median follow-up for FBT and WBT groups were 34 months (range: 10-68 months) and 24 months (range: 24-36 months), respectively. There was no difference in recurrence rates between-groups (FBT 7.5% vs. WBT 3%, p = 0.35) (fig. 1). WBT group had significant worsening of urinary symptoms when compared to FBT group at 6 months (p = 0.003), but not with 12 and 24 months. Urinary continence and sexual function was similar between-groups. CONCLUSIONS FBT has satisfactory oncological outcomes and less urinary symptoms at early follow-up when compared to WBT. Urinary continence and sexual functional is the same as WBT. © 2017FiguresReferencesRelatedDetails Volume 197Issue 4SApril 2017Page: e1364-e1365 Advertisement Copyright & Permissions© 2017MetricsAuthor Information Victor Srougi More articles by this author Eric Barret More articles by this author Mohammed Baghdadi More articles by this author Igor Nunes-Silva More articles by this author Silvia Garcia-Barreras More articles by this author Gregory Rembeyo More articles by this author François Rozet More articles by this author Marc Galiano More articles by this author Rafael Sanchez-Salas More articles by this author Jean Cosset More articles by this author Xavier Cathelineau More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...